|
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer |
|
|
|
Titel: |
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer |
Auteur: |
Li, Ning Qiu, Meng Zhang, Yanqiao Yang, Mudan Lu, Linzhi Li, Wei Ma, Yuntao Hou, Xiaoming Sun, Guoping Cai, Mingquan Wang, Jingran Lu, Jianwei Zhong, Diansheng Huo, Zhibin Zhang, Jingdong Yin, Xianli Deng, Jun Liu, Zimin Pan, Hongming Chen, Ye Yang, Futang Yu, Haoyu Li, Jing Wang, Qingyu Zhu, Jun Li, Jin |
Verschenen in: |
Med |
Paginering: |
Jaargang 5 () nr. 10 pagina's 1255-1265.e2 |
Jaar: |
2024 |
Inhoud: |
|
Uitgever: |
Elsevier Inc. |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|